Answers are grounded in this paper and cite their sources.
Background: The clinical value of topical nasal vasoconstrictors such as xylometazoline, oxymetazoline, and adrenaline before flexible bronchoscopy remains uncertain. Previous randomized controlled trials (RCTs) show conflicting findings. In this meta-analysis, we combine the conflicting results of RCTs evaluating topical nasal vasoconstrictors in patients undergoing flexible bronchoscopy. Methods: We searched four major databases from inception till 7 August 2026. Efficacy outcomes were the time to reach the vocal cords, nasal mucosal injury, patient-reported nasal pain, and assistant-rated facial pain; physiological tolerability was assessed as changes in heart rate, blood pressure, oxygen saturation, and respiratory rate. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were pooled with DerSimonian–Laird random-effects models, with Hartung–Knapp–Sidik–Jonkman (HKSJ) and comparator-specific sensitivity analyses, and the certainty of evidence was rated with GRADE. Results: The systematic review included four RCTs, whereas quantitative pooling was possible for three. Pooled estimates showed no statistically significant advantage of topical nasal vasoconstrictors for vocal-cord access time (SMD = −0.56, 95% CI [−1.30: 0.18], p = 0.14), nasal mucosal injury (SMD = −0.64, 95% CI [−1.31: 0.03], p = 0.06), patient nasal pain (SMD = −0.47, 95% CI [−1.62: 0.68], p = 0.42), or assistant-rated facial pain (SMD = −0.63, 95% CI [−1.87: 0.60], p = 0.32); heterogeneity was very high (I2 = 90–98%), HKSJ intervals were wider, and the certainty of evidence was very low. No clear between-group differences were detected in the physiological parameters (low to very low certainty), and reported adverse events were few. Conclusions: The available randomized evidence does not demonstrate a benefit of topical nasal vasoconstrictors over conventional nasal preparation before flexible bronchoscopy, but the estimates are imprecise and inconsistent and do not establish equivalence. The absence of clear differences in physiological parameters indicates short-term tolerability in the mostly unsedated, cardiovascularly stable populations studied, not proven safety.
No takes yet. Share an insight, caveat, or question.
Albannai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: